PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 23, issue 12, 2005

The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply pp. 1193-1202

Joseph DiMasi and Cherie Paquette

Willingness to pay for inhaled insulin pp. 1215-1227

Hamid Sadri, Linda MacKeigan, Lawrence Leiter and Thomas Einarson

Volume 23, issue 10, 2005

Pharmacological management of overactive bladder pp. 995-1006

Denis Getsios, Wissam El-Hadi, Ingrid Caro and J. Caro

The cost effectiveness of orlistat in a 1-year weight-management programme for treating overweight and obese patients in Sweden pp. 1007-1020

Peter Hertzman

Eplerenone pp. 1057-1072

Katherine Croom and Greg Plosker

Volume 23, issue 6, 2005

The economics of topical immunomodulators for the treatment of atopic dermatitis pp. 543-566

William Abramovits, Mark Boguniewicz, Amy Paller, Diane Whitaker-Worth, Mary Prendergast, Michael Tokar and Kuo Tong

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease pp. 619-637

Michael Spencer, Andrew Briggs, Ronald Grossman and Laureen Rance

Volume 22, issue 15, 2004

Economic Impact of Migraine and Other Episodic Headaches in France pp. 985-999

André Pradalier, Jean-Paul Auray, Abdelkader Hasnaoui, Kazem Alzahouri, Jean-François Dartigues, Gérard Duru, Patrick Henry, Michel Lantéri-Minet, Christian Lucas, Guy Chazot and Anne-François Gaudin

Volume 21, issue 1, 2003

Generic Clozapine pp. 1-11

Gordon Tse, Deborah Thompson and Ric Procyshyn

Economic Evaluations of Varicella Vaccination Programmes pp. 13-38

Nancy Thiry, Philippe Beutels, Pierre Damme and Eddy Doorslaer

Advantages of Using the Net-Benefit Approach for Analysing Uncertainty in Economic Evaluation Studies pp. 39-48

Niklas Zethraeus, Magnus Johannesson, Bengt Jönsson, Mickael Löthgren and Magnus Tambour

Potential Costs and Effects of the National Service Framework for Coronary Heart Disease in the UK pp. 49-60

Venanzio Vella

Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting pp. 61-74

W. Simons

Volume 19, issue 5, 2001

Hip Fracture Prevention pp. 449-468

Peter Vestergaard, Lars Rejnmark and Leif Mosekilde

The Lifetime Cost of Bipolar Disorder in the US pp. 483-495

Charles Begley, John Annegers, Alan Swann, Christopher Lewis, Sharon Coan, William Schnapp and Lynda Bryant-Comstock

Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension pp. 497-512

Peter Schädlich, Josef Brecht, Massimo Brunetti, Eva Pagano, Badrudin Rangoonwala and Eduard Huppertz

Volume 17, issue 4, 2000

The Importance of Achieving Additional Drug Benefits at a Reasonable Cost pp. 319-324

Nick Freemantle and James Mason

Cost Effectiveness of Combination HIV Therapy pp. 325-330

Richard Moore

Economic Burden of Irritable Bowel Syndrome pp. 331-338

Michael Camilleri and Donald Williams

Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio pp. 339-349

Anthony O’Hagan, John Stevens and Jacques Montmartin

Potential Savings in the Cost of Caring for Alzheimer’s Disease pp. 351-360

A. Hauber, Ari Gnanasakthy, Edward Snyder, Mohan Bala, Anke Richter and Josephine Mauskopf

Costs Incurred by Patients Undergoing Advanced Colorectal Cancer Therapy pp. 361-370

Mark Sculpher, Michael Palmer and Anne Heyes

Initial Treatment Choice in Depression pp. 371-382

Eric Edgell, Timothy Hylan, JoLaine Draugalis and Stephen Coons

Cost Analysis of the Treatment of Schizophrenia in the UK pp. 383-389

Stephen Almond and Owen O’Donnell

Cost Effectiveness of Competing Strategies to Prevent or Treat GORD-Related Dysphagia pp. 391-401

Amnon Sonnenberg

Volume 14, issue 6, 1998

Are Mental Health Services Losing Out in the US Under Managed Care? pp. 597-601

Dale Johnson

Thrombolysis, Stroke Units and Other Strategies for Reducing Acute Stroke Costs pp. 603-611

Theodore Wein, Susan Hickenbottom and Andrei Alexandrov

A Review of Quality of Life in Alzheimer’s Disease pp. 613-627

Sam Salek, Melvyn Walker and Antony Bayer

Insomnia, Health-Related Quality of Life and Healthcare Resource Consumption pp. 629-637

Hind Hatoum, Sheldon Kong, Christopher Kania, Josephine Wong and Wallace Mendelson

The Use and Cost of HIV Service Provision in England in 1996 pp. 639-652

Eduard Beck, Keith Tolley, Amanda Power, Sundhiya Mandalia, Philippa Rutter, Junichi Izumi, Jeni Beecham, Alastair Gray, David Barlow, Philippa Easterbrook, Martin Fisher, John Innes, George Kinghorn, Bibhat Mandel, Anton Pozniak, Allan Tang, David Tomlinson and Ian Williams

Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction pp. 653-669

Peter Schädlich, Eduard Huppertz and Josef Brecht

Cost-Effectiveness Analysis of Formoterol Versus Salmeterol in Patients with Asthma pp. 671-684

Maureen Mölken, Eddy Doorslaer and M. Till

Fosphenytoin pp. 685-690

Stephen Holliday, Paul Benfield and Greg Plosker

Cyclosporin Microemulsion (Neoral®)† pp. 691-708

Allan Coukell and Greg Plosker

A Short Term Cost-Effectiveness Model for Oral Antidiabetic Medicines in Europe pp. 709-709

Linda MacKeigan

The authors reply pp. 710-711

Sheila Hood, Lieven Annemans and Maureen Mölken

Common Errors and Controversies in Pharmacoeconomic Analyses pp. 711-712

Javier Soto

Volume 11, issue 6, 1997

Erratum to Will Managed Care Work in Europe? pp. 594-594

Elias Mossialos, P. Kanavos and B. Abel-Smith

Volume 11, issue 3, 1997

Erratum to Rational prescribing of antibacterials in ambulatory children pp. 286-286

Hoppe Je

Volume 11, issue 2, 1997

Economic Evaluation Techniques in Healthcare pp. 115-118

Alan Maynard

The Role of the US Food and Drug Administration’s Patient Information Initiative in Cost-Effective Drug Therapy pp. 119-125

Stuart Nightingale and Thomas McGinnis

The Economics of Osteoporosis and Its Prevention pp. 126-138

David Torgerson and David Reid

The Economics of Pharmacotherapy for Diabetes Mellitus pp. 139-158

Bernardo Costa, Jaume Arroyo and Angels Sabaté

Guidelines for Pharmacoeconomic Studies pp. 159-168

Joanna Siegel, George Torrance, Louise Russell, Bryan Luce, Milton Weinstein and Marthe Gold

An Economic Evaluation of the Use of Granulocyte Colony-Stimulating Factor After Bone Marrow Transplantation in Children pp. 169-174

Nicholas Duncan, Margaret Hewetson, Ayad Atra, Gina Dick and Ross Pinkerton

Differences in the Methodology and Data of Economic Evaluations of a Health Programme pp. 175-183

Xavier Badia, Gonzalo Nocea and Joan Rovira

Terazosin pp. 184-197

Greg Plosker and Karen Goa